C3aRA was used in vivo to confirm the complement effect on neurological changes to further determine whether Sig-1R activation-mediated synaptic improvement was due to a decrease in C3/C3a level in the brain of mice with T1DM. The gene discussed is SIGMAR1; the disease is type 1 diabetes mellitus.